- The global market for laboratory-developed tests reached nearly $9.7 billion in 2015. This market is expected to increase from nearly $11.0 billion in 2016 to $14.9 billion in 2021 at a compound annual growth rate (CAGR) of 6.3% for 2016-2021. - Specialty lab market is expected to grow from $1.6 billion in 2016 to nearly $2.1 billion at a CAGR of 5.9% from 2016 through 2021. - Reference lab market is expected to grow from nearly $9.4 billion in 2016 to $12.7 billion in 2021 at a CAGR of 6.3% from 2016 through 2021.
Study Goals and Objectives This report will focus on companies that rely on laboratory-developed testing for at least 10% of their revenue. This is meant to avoid focusing on companies and laboratories that occasionally offer laboratory-developed tests to deal with unique patient needs.
This report will also focus on the suppliers of the analyte-specific reagents used within these laboratory-developed tests, as their contract manufacturing is key to the successful development of these tests. While various technologies will be highlighted in relation to their use in laboratory-developed testing, we will not explore the markets for these different technologies in depth.
Reasons for Doing This Study Laboratory discoveries have long been a source of clinical diagnostics products, and these discoveries have regularly developed into Food and Drug Administration-regulated in vitro diagnostics. This transition involves a number of preclinical and clinical testing steps to validate both the accuracy of the test and the clinical relevance of the test prior to FDA approval and product marketing.
The goal is to make sure such a product is safe and effective for the treatment and diagnosis of disease, and the regulatory regime has been effective in protecting the public from clinical diagnostics that are not effective from being broadly marketed.
However, there are a number of laboratory discoveries useful for clinical diagnostics that are novel, unique or esoteric. These particular tests offer particular benefits for patients, but it may not be feasible to go through the FDA approval process for a variety of reasons, such as public health, low market demand or the introduction of a new technology. The clinical diagnostics market has long seen tests marketed by individual clinical laboratories, and a number of new technologies, along with the ability to market nationally, have made it possible for some companies to make the marketing of laboratory- developed tests an industry in and of itself.
Scope of Report This report will focus on companies that rely on laboratory-developed testing for at least 10% of their revenue. This is meant to avoid focusing on companies and laboratories that occasionally offer laboratory-developed tests to deal with unique patient needs.
This report will also focus on the suppliers of the analyte-specific reagents used within these laboratory-developed tests, as their contract manufacturing is key to the successful development of these tests. While various technologies will be highlighted with relation to their use in laboratory-developed testing, we will not explore the markets for these different technologies in depth.
Information Sources Information sources for this report include research of scientific articles, primary sourcing interviews with key contacts within the industry, and review of industry financial statements and government regulatory and patent filings.
Methodology The intended audiences for this are those who work around the clinical diagnostics industry. This includes laboratory professionals, management, quality control, and sales and marketing staff within clinical laboratories.
Firms that manufacture analyte-specific reagents will take a particular interest in this report as well, as demand for their reagents will be significantly influenced by the development of laboratory-developed tests. People with an interest in the biotechnology industry as a whole will have an interest in this report, as biotechnology firms are broadening their interest beyond pharmaceutical treatments in part or in whole, and the laboratory-developed testing industry is a strong part of such an industry.
Summary and Highlights The laboratory-developed test marketplace will grow from nearly $11 billion in 2016 to almost $14.9 billion in 2021, with a compound annual growth rate (CAGR) of 6.3%. Reference laboratory revenue in this marketplace will grow from nearly $9.4 billion in 2016 to $12.7 billion in 2021, with a CAGR of 6.3%.
Specialty laboratories will grow from $1.6 billion in revenue in 2016 to $2.1 billion in 2021, with a CAGR of 5.9%. The laboratory-developed test marketplace is evolving due to a variety of technological, financial and regulatory factors that will shift the testing mix and drive higher usage of these tests within the wider clinical diagnostics marketplace.
Key Trends PAMA Is Taking a Hammer to Laboratory Test Prices The Protection of Access to Medicare and Medicaid Act, commonly referred to as PAMA, gives the federal government the authority to survey prices for all laboratory tests and come up with a standard price to pay for such tests. Such standard prices are anticipated to be lower than what many laboratories currently charge. For LDTs (Laboratory Developed Tests), PAMA is anticipated to have a major impact due to the way they are currently billed. As private insurance payment rates are commonly based on a premium to Medicare and Medicaid rates, any rate cuts have a potential for widespread financial impact to LDT providers.
Regulatory Discretion Impacts Certain LDTs The FDA has decided to only target laboratories that provide LDTs that present a particular risk to human health. However, a series of recent forums has displayed the agency’s thinking on such tests. In particular, serology and molecular diagnostics tests appear to be in the regulatory crosshairs. There are notable concerns about what constitutes a medical device versus a service, which has wide-ranging impacts on what tests may be allowed.
Genomics Testing Comes of Age Genomics testing has matured enough that laboratories are investing significantly in sequencing equipment, and genomic-based tests are rolling out on these new platforms. Testing is being introduced that both replaces and complements existing molecular diagnostics. It is also creating new opportunities for pathologists to perform analyses that have been heretofore technically difficult or even impossible.
Testing Mix Shifts within LDTs As genomic testing comes of age and the sensitivity of mass spectrophotometry (MS) testing has come to be recognized, there are broader platform shifts going on within the LDT marketplace. Serological and molecular diagnostics tests are maturing out of the market, while new genomic and MS-based tests are being introduced to replace and improve those tests.
Consolidation of the LDT Marketplace As a part of the wider clinical diagnostics marketplace, more LDTs are being performed by national and regional reference laboratories. Smaller laboratories and academic laboratories are reducing testing volumes. While a number of smaller specialty players exist, high capital costs and lower reimbursement rates are making it difficult for smaller laboratories to keep up with their larger counterparts.
The Understated Importance of Mass Spectrophotometry LDTs Mass spectrophotometry (MS)-based tests have long been a key part of the LDT marketplace. However, the increased sensitivity of such technology is being leaned on for a variety of applications traditionally dependent on serological testing. In addition, new applications based on increased understanding of therapeutic drug monitoring and DNA (deoxynucleic acid) analysis are increasing the opportunities for this platform to be used with LDTs.
Our reports have been used by over 10K customers, including:
Europe cancer screening market Europe after North America is the second largest market leading the cancer screening market. The market is forecasted to grow at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the forecast period (2018-2023). Increase in the aging population along...
In the report the esoteric testing market, the market is expected to reach US$ $ 45,081.6 Mn in 2025 from US$ 19,868.2 in 2017. The market is estimated to grow with a CAGR of 11.7% from 2018-2025. The esoteric testing market is driven by the driving factor such as rising prevalence of infectious diseases, growing awareness regarding early...
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country.Contains 11 pages and 3 tables
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories performing infectious disease tests, as well as ten-year test volume and sales forecasts by country.Contains 15 pages and 3 tables
KEY FINDINGS The global laboratory filtration market is expected to grow with a CAGR of 6.87% during the forecasted period 2019-2027. Laboratory filtration helps in removal of pollutants such as fine sediment particulates and phosphorus & nitrogen particulate species. These media filters are also used for industrial, commercial...
2018 Coagulation POC and Laboratory Instrumentation, and Strategic Profiles of Leading Suppliers This 71-page report reviews current instrumentation technologies, and compares features of leading automated and semiautomated analyzers.
This report provides estimates of the number of laboratories performing tumor marker assays, as well as test volume and sales forecasts by country.The report also presents strategic analyses of leading current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution...
About This ReportThis new 283-page report presents detailed analysis of the US Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections...
This new 148-page report from VPGMarketResearch.com reviews current instrumentation technologies, and profiles features of leading automated and semi-automated Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic analyzers. The report also presents strategic assessments...
This report provides a worldwide overview of the transfusion testing market, including estimates of facilities performing transfusion testing tests, as well as test volume, reagent and instrument sales forecasts for blood typing, grouping and infectious disease screening tests by country.Contains 15 pages and 5 tables
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.